321 related articles for article (PubMed ID: 16227523)
1. Natural history of Fabry disease in females in the Fabry Outcome Survey.
Deegan PB; Baehner AF; Barba Romero MA; Hughes DA; Kampmann C; Beck M;
J Med Genet; 2006 Apr; 43(4):347-52. PubMed ID: 16227523
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
3. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
[TBL] [Abstract][Full Text] [Related]
4. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
5. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
[TBL] [Abstract][Full Text] [Related]
6. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
8. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
9. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.
Hughes DA; Barba Romero MÁ; Hollak CE; Giugliani R; Deegan PB
Mol Genet Metab; 2011 Jul; 103(3):207-14. PubMed ID: 21543245
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.
Mehta A; Beck M; Elliott P; Giugliani R; Linhart A; Sunder-Plassmann G; Schiffmann R; Barbey F; Ries M; Clarke JT;
Lancet; 2009 Dec; 374(9706):1986-96. PubMed ID: 19959221
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
[TBL] [Abstract][Full Text] [Related]
14. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.
Whybra C; Kampmann C; Krummenauer F; Ries M; Mengel E; Miebach E; Baehner F; Kim K; Bajbouj M; Schwarting A; Gal A; Beck M
Clin Genet; 2004 Apr; 65(4):299-307. PubMed ID: 15025723
[TBL] [Abstract][Full Text] [Related]
15. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
16. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
17. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
19. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
20. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.
Linhart A; Kampmann C; Zamorano JL; Sunder-Plassmann G; Beck M; Mehta A; Elliott PM;
Eur Heart J; 2007 May; 28(10):1228-35. PubMed ID: 17483538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
